Beclin 2 negatively regulates innate immune signaling and tumor development

Motao Zhu,Guangtong Deng,Peng Tan,Changsheng Xing,Cuiping Guan,Chongming Jiang,Yinlong Zhang,Bo Ning,Chaoran Li,Bingnan Yin,Kaifu Chen,Yuliang Zhao,Helen Y. Wang,Beth Levine,Guangjun Nie,Rong-Fu Wang

DOI: https://doi.org/10.1172/jci133283

IF: 19.456

2020-08-31

Journal of Clinical Investigation

Abstract:Beclin 2 plays a critical role in metabolic regulation and obesity, but its functions in innate immune signaling and cancer development remain largely unknown. Here, we identified Beclin 2 as a critical negative regulator of inflammation and lymphoma development. Mice with homozygous ablation of BCL2-interacting protein 2 (<i>Becn2</i>) developed splenomegaly and lymphadenopathy and markedly increased ERK1/2 and NF-κB signaling for proinflammatory cytokine production. Beclin 2 targeted the key signaling kinases MEKK3 and TAK1 for degradation through an ATG9A-dependent, but ATG16L/Beclin 1/LC3–independent, autophagic pathway. Mechanistically, Beclin 2 recruited MEKK3 or TAK1 through ATG9A to form a complex (Beclin 2-ATG9A-MEKK3) on ATG9A⁺ vesicles upon ULK1 activation. Beclin 2 further interacted with STX5 and STX6 to promote the fusion of MEKK3- or TAK1-associated ATG9A⁺ vesicles to phagophores for subsequent degradation. Importantly, <i>Becn2</i>-deficient mice had a markedly increased incidence of lymphoma development, with persistent STAT3 activation. Myeloid-specific ablation of MEKK3 (<i>Map3k3</i>) completely rescued the phenotypes (splenomegaly, higher amounts of proinflammatory cytokines, and cancer incidence) of <i>Becn2</i>-deficient mice. Hence, our findings have identified an important role of Beclin 2 in the negative regulation of innate immune signaling and tumor development through an ATG9A-dependent, but ATG16L/Beclin 1/LC3–independent, autophagic pathway, thus providing a potential target for the treatment of inflammatory diseases and cancer.

medicine, research & experimental